Angion Biomedica (ANGN) Stock Price, News & Analysis

Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.00 to $10.00
• 52-Week Range: N/A
• Volume: 224,800 shs
• Average Volume: 86,718 shs
• Market Capitalization: $30.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANGN Stock Analysis - Frequently Asked Questions

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings data on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, beating the consensus estimate of ($7.30) by $2.00. The firm had revenue of $1.46 million for the quarter, compared to analysts' expectations of $1.08 million.

When did Angion Biomedica's stock split?

Angion Biomedica's stock reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

Angion Biomedica (ANGN) raised $75 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What other stocks do shareholders of Angion Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ANGN
• CIK: 1601485
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.81 million
• Net Margins: N/A
• Pretax Margin: -4,456.97%
• Return on Equity: -47.53%
• Return on Assets: -40.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.00
• Quick Ratio: 20.00

Sales & Book Value

• Annual Sales: $2.30 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 30,110,000
• Free Float: 24,182,000
• Market Cap: $30.11 million
• Optionable: Not Optionable
• Beta: 0.60